Monday, September 21, 2026
Invest Strategies Group
  • Investing
  • Economy
  • Business
  • Stock
No Result
View All Result
Invest Strategies Group
  • Investing
  • Economy
  • Business
  • Stock
No Result
View All Result
Invest Strategies Group
No Result
View All Result
Home Stock

DexCom Stock Rises From the Ashes: A Breakout You Can’t Ignore

admin by admin
January 18, 2025
in Stock
0
DexCom Stock Rises From the Ashes: A Breakout You Can’t Ignore
0
SHARES
6
VIEWS
Share on FacebookShare on Twitter

As advancements in medical technology continue to shape the healthcare landscape, DexCom, Inc. (DXCM) stands out with its innovative continuous glucose monitoring solutions. Recent price action suggests that DXCM’s stock price has triggered a potentially new bullish run. In this article, I will examine the technical and fundamental factors behind this positive outlook and outline a risk-defined options strategy — all identified via the OptionsPlay Strategy Center within StockCharts.com.

After consolidating between $75 and $80 over the past two months, DXCM’s stock price recently broke out of this trading range with impressive relative strength.

  • Range Breakout. The stock’s breakout above $80 marks a decisive breakout from its consolidation zone.
  • Outperformance. The breakout has been coupled with outperformance to the S&P 500.
  • Upside Target. Given the breakout, there is potential for DXCM’s stock price to fill the gap up to the $107.50 level.

FIGURE 1. DAILY CHART OF DXCM STOCK. The stock price traded between $75 and $80 since the end of November. DXCM recently broke out of its consolidation zone and traded above $80.Chart source: StockCharts.com. For educational purposes.

Beyond the charts, DXCM’s fundamentals support its premium valuation:

  • Premium but justified. While trading at 39x forward earnings, DXCM’s superior growth expectations and higher net margins than peers suggest that this valuation is justified.
  • Potential for substantial upside. Robust demand in the continuous glucose monitoring market and DexCom’s leadership position the company to capitalize on ongoing trends. The combination of strong growth prospects and healthy margins provides the potential for further appreciation.

Options Strategy

Based on this bullish thesis, the OptionsPlay Strategy Center highlights a bull put spread.

  • Sell: February 28, 2025, $84 Put at $5.40
  • Buy: February 28, 2025, $77 Put at $2.42
  • Net Credit: $2.98 per share (or $298 total per contract, since each contract represents 100 shares)

FIGURE 2. DXCM BULL PUT SPREAD RISK CURVE.

Trade Details

  • Maximum Potential Reward: $298
  • Maximum Potential Risk: $402
  • Breakeven Point: $81.02
  • Probability of Profit: 58.58%

This strategy benefits from time decay and a bullish outlook, providing limited risk and a defined reward. At expiration, profits are earned if DXCM’s stock price remains above the breakeven level.

Unlock Real-Time Trade Ideas

This bullish trade in DXCM was identified using the OptionsPlay Strategy Center within StockCharts.com. The platform’s Bullish Outperform scan (see below) automatically flagged DXCM as the best candidate for selling a Bull Put Spread out of the many stocks currently outperforming the market, then structured the optimal options trade — helping you save hours of research.

FIGURE 3. BULLISH OUTPERFORMANCE SCAN. DXCM was identified as a candidate for a bull put spread.


By subscribing to the OptionsPlay Strategy Center, you gain access to:

  •  Automated Market Scans. Quickly discover high-probability trading opportunities based on technical and fundamental signals.
  • Optimal Trade Structuring. Receive tailored, real-time options strategies for your market outlook and risk tolerance.
  • Time-Saving Insights. Make informed decisions faster, avoiding the time-consuming process of manual analysis.

Don’t miss out on your next high-conviction idea. Subscribe to the OptionsPlay Strategy Center today and unlock a streamlined approach to uncovering the best options trades—all within seconds, every single day. Let OptionsPlay be your strategic ally in navigating the markets efficiently and effectively.

Previous Post

Bold Ventures Showcases New Gold Discovery and Recent New Results at Vancouver Resource Conferences

Next Post

Long Bonds Continue to Break Down

admin

admin

Next Post
Long Bonds Continue to Break Down

Long Bonds Continue to Break Down

    Subscribe to our newsletter for early access to new products, exclusive deals, and exciting updates. Don't miss out! Our subscribers are always the first to hear about limited-time offers and new arrivals. Plus, you'll get sneak peeks and bonus content that adds value to your experience.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recommended

    Kobo Resources Closes Second and Final Tranche of the Upsized Non-Brokered Private Placement for Gross Proceeds of Over $3.96 Million

    Kobo Resources Closes Second and Final Tranche of the Upsized Non-Brokered Private Placement for Gross Proceeds of Over $3.96 Million

    September 15, 2025
    Financial analyst reviews numbers and charts on a screen

    TFSA Passive Income: 2 Top TSX Stocks Finally Trading at a Discount

    September 9, 2026

    Recent News

    Blaize (BZAI) Q2 2026 Earnings Call Transcript

    3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026

    September 20, 2026
    The House | Angus MacDonald: "If You're Active In Faith, You're More Likely To Have A Moral Compass"

    The House | Angus MacDonald: “If You’re Active In Faith, You’re More Likely To Have A Moral Compass”

    September 20, 2026
    AMC Robotics Secures Up to $50M Equity Facility to Fund Robot Manufacturing Plant

    AMC Robotics Secures Up to $50M Equity Facility to Fund Robot Manufacturing Plant

    September 20, 2026
    Blaize (BZAI) Q2 2026 Earnings Call Transcript

    Buying This Hidden Software Stock Might Just Give You Massive Exposure to the Anthropic IPO

    September 20, 2026
    Invest Strategies Group

    Browse by Category

    • Business
    • Economy
    • Investing
    • Stock

    Recent News

    Blaize (BZAI) Q2 2026 Earnings Call Transcript

    3 Reasons CRISPR Therapeutics Stock Is Still a Buy After a Rocky 2026

    September 20, 2026
    The House | Angus MacDonald: "If You're Active In Faith, You're More Likely To Have A Moral Compass"

    The House | Angus MacDonald: “If You’re Active In Faith, You’re More Likely To Have A Moral Compass”

    September 20, 2026
    • Terms & Conditions
    • Privacy Policy

    Copyright © 2026 investstrategiesgroup.com | All Rights Reserved

    No Result
    View All Result
    • Home 1
    • Privacy Policy
    • Terms & Conditions
    • Thank you

    Copyright © 2026 investstrategiesgroup.com | All Rights Reserved